This makes pharmacological inhibition of NaV1.7 an exciting therapeutic strategy for the treatment of a wide range of pain types, including inherited erythromelalgia and paroxysmal extreme pain disorder, two conditions whose pathophysiology arises from NaV1.7 gain-of-function mutations. The gene discussed is SCN9A; the disease is paroxysmal extreme pain disorder.